The Proteasome Subunit Beta Type 8 pipeline drugs market research report outlays comprehensive information on the Proteasome Subunit Beta Type 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Proteasome Subunit Beta Type 8 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Gastrointestinal, Musculoskeletal Disorders, and Oncology which include the indications Psoriasis, Autoimmune Disorders, Inflammatory Bowel Disease, Autoimmune Hepatitis, Polymyositis, Dermatomyositis, and Unspecified Cancer. It also reviews key players involved in Proteasome Subunit Beta Type 8 targeted therapeutics development with respective active and dormant or discontinued products.
The Proteasome Subunit Beta Type 8 pipeline targets constitutes close to four molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 1, and 2 respectively.
Proteasome Subunit Beta Type 8 overview
Proteasome 20S subunit beta 8 also known as 20S proteasome subunit beta-5i is a protein that in humans is encoded by the PSMB8 gene. This gene is in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.
For a complete picture of Proteasome Subunit Beta Type 8’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
